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Abstract: H5N1 avian influenza is a significant global concern with the potential to become 
the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pan-
demic vaccines compared to traditional vaccine technologies. In particular, polyanhydride 
nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-
mediated immunity and provide protection upon lethal challenge. In this work, a recombinant 
H5 hemagglutinin trimer (H5
3
) was produced and encapsulated into polyanhydride nanoparticles. 
The studies performed indicated that the recombinant H5
3
 antigen was a robust immunogen. 
Immunizing mice with H5
3
 encapsulated into polyanhydride nanoparticles induced high neutral-
izing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H5
3
-based 
polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral 
challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and 
subsequently challenged with virus were similar to naïve mice that were not challenged. The 
current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines 
in pandemic scenarios.
Keywords: polymer, nanoparticle, vaccine, subunit, neutralizing antibody
Introduction
Influenza virus is a major cause of serious respiratory illness and has been respon-
sible for significant morbidity and mortality in humans worldwide. The major strains 
of influenza A virus circulating in human populations are H3N2 and H1N1, which 
are associated with seasonal influenza viral infections. In addition, the avian strains 
H5N1 and H7N9 have been found to infect humans;1 however, they are not currently 
capable of sustained human-to-human transmission. Should these highly pathogenic 
avian viruses develop such capability, the disease could spread rapidly, resulting in a 
global influenza pandemic. Vaccination represents a critical control measure against 
yearly seasonal influenza viruses and is an essential component of pandemic prepared-
ness plans.2 Nearly all of the current influenza vaccine technologies are based on the 
use of embryonated eggs and require a relatively long production cycle, resulting in 
limited manufacturing capacity.2 The response to the 2009 H1N1 pandemic clearly 
demonstrated the limitations of vaccine production methods with respect to rapid 
deployment, which led to vaccine shortages. Consequently, there is great interest in 
developing new technologies for rapid, large-scale production of safe and efficacious 
influenza vaccines.
Recombinant hemagglutinin (rHA)-based vaccines produced in mammalian or 
insect cell culture systems are attractive alternatives to egg-based vaccine technologies.3 
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Production and purification of rHA protein can effectively 
reduce the vaccine production time and the use of cell culture 
systems may glycosylate proteins, which is important for 
the development of neutralizing antibodies against receptor-
binding site epitopes.4 Recent studies demonstrated that rHA 
engineered to form a stable trimeric configuration elicited 
a protective immune response in vaccinated animals.5–10 
Neutralizing antibody levels and protection from disease 
were enhanced in mice vaccinated with soluble rHA trimers 
as compared to animals vaccinated with rHA monomers,5,8 
indicating the importance of immunogens that mimic those 
expressed by the infectious agent. Along these lines, the 
composition and/or number of N-linked glycans on rHA 
trimers have been shown to modify the level of the protec-
tive antibody response.10,11 All of these studies indicate that 
rHA trimers could be an important component of a subunit 
vaccine strategy against influenza.
Hemagglutinin (HA)-specific serum antibody titers cor-
relate with protection from disease; however, recombinant 
proteins are often weak immunogens and require multiple, 
high-dose immunizations to achieve protection.6,7,12 Poly-
anhydride nanoparticles have been shown to be a versatile 
vaccine adjuvant/delivery platform capable of enhanc-
ing the immune response to recombinant proteins.13–15 
Polyanhydrides are biodegradable materials that provide 
sustained release kinetics of encapsulated antigens, result-
ing in long-lived, high-avidity antibody titers, even with 
suboptimal doses of antigen.13–15 In addition to amplifying 
humoral immunity, polyanhydride nanoparticle–based 
vaccines (ie, nanovaccines) have been shown to be 
immunomodulatory16 and are capable of promoting cell-
mediated immunity. Previous work with polyanhydride 
nanovaccines indicated expansion of antigen-specific CD8+ 
T cells following nanovaccine immunization, resulting 
in memory T cell populations that responded to antigen-
expressing tumor challenge (CD8+ T cells).17 This broad 
repertoire of immune responses induced by polyanhydride 
nanovaccines may prove beneficial for influenza vaccine 
efficacy because robust cell-mediated responses are often 
associated with broader protective immunity and directed 
at conserved epitopes.18,19
Previously, soluble H5 HA trimers (sH5
3
) from H5N1 
influenza virus A/Whooper Swan/Mongolia/244/05 were 
produced using a baculovirus insect cell expression system 
and shown to maintain their oligomeric structure and anti-
genicity upon release from polyanhydride nanoparticles.20 
In this study, the immunogenicity and virus-neutralizing 
antibody titer in response to nanovaccine immunization were 
observed for approximately 2 months, and concluded with 
an analysis of memory T cell responses. Finally, the efficacy 
of the nanovaccine formulations was examined using a low-
pathogenic, live-viral challenge. The data demonstrate that 
polyanhydride nanovaccines containing immunogenic HA 
trimer represent a potentially viable platform for pandemic 
influenza vaccines.
Materials and methods
Plasmids and antibody
Plasmid pHW500 (Genbank DQ659326), obtained from 
Dr Bruce Janke of Iowa State University, contains the full-
length HA gene from HPAI H5N1 influenza virus A/Whooper 
Swan/Mongolia/244/05 (H5N1). The pHW500 HA gene was 
modified by replacement of the cognate polybasic cleavage 
site with that from a low-pathogenic H6N1 avian influenza 
virus.21 The FDA-VN plasmid, obtained from Dr Carol Weiss 
of the US Food and Drug Administration, contains the full-
length HA from A/Vietnam/1203/2004 (H5N1) (Genbank 
EF541403) in pCMV/R.22 The pWS-HA was constructed 
by replacing the H5 Vietnam HA gene in FDA-VN with the 
HA gene from pHW500. The low-pathogenic cleavage site 
in pWS-HA was replaced with the polybasic cleavage site 
from A/Whooper Swan/Mongolia/3/05 (H5N1) (Genbank 
AB233320.1). The equine infectious anemia lentivirus vector 
plasmids pEV53B and pSIN6.1ClucW were obtained from 
John Olsen.23 Hyperimmune swine sera containing high titers 
of H5 neutralizing antibody was obtained from Dr Bruce 
Janke.21 H5-specific polyclonal rabbit antisera was obtained 
from Dr Carol Weiss.22
cloning and expression of soluble h5 
trimer (sh53)
The HA ectodomain (nucleotides 1–1,723) was amplified 
from pHW500 and modified at the 3′ end by addition of 
linker sequences, a GCN4pII trimerization domain,8 and 
His-tag sequences (Figure 1A). The modified gene was 
cloned into pFastBac I, transformed into DH10Bac cells, 
and recombinant baculoviruses were generated using Bac-
to-Bac Baculovirus Expression System (Thermo Fisher 
Scientific, Waltham, MA, USA). Sf9 cells (Thermo Fisher 
Scientific) were infected with recombinant baculovirus and 
supernatants collected 96 hours after infection were clari-
fied by centrifugation, dialyzed against 10 mM Tris buffer 
(10 mM Tris, 50 mM NaCl, pH 8.0), and incubated with 
Ni-NTA beads (Thomas Scientific, Swedesboro, NJ, USA) 
overnight at 4°C. The beads were washed with 10 mM 
Tris buffer containing 10 mM imidazole and recombinant 
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sH5
3
 was eluted in 10 mM Tris buffer containing 250 mM 
imidazole. The eluted proteins were dialyzed against 10 
mM Tris buffer to remove imidazole, concentrated, and 
stored at 4°C for up to 1 month or at -80°C for long-term 
storage.
ha-pseudotyped reporter virus
HA-pseudotyped viruses were produced in HEK293T cells 
as described previously.22,24 Briefly, HEK293T cells were 
cotransfected with 5 μg of pEV-53B encoding the lentivi-
ral core proteins of equine infectious anemia virus, 5.5 μg 
of the luciferase reporter plasmid plgSIN6.1Luc, and 1 μg 
of pFDA-VN or pWS-HA plasmid DNA expressing HA 
from A/Vietnam/1203/2004 (clade 1) or A/Whooper Swan/
Mongolia/244/05 (clade 2.2), respectively. At 18 hours post-
transfection, cells were incubated with fresh medium contain-
ing 7 mU/mL of Vibrio cholerae Type II neuraminidase (NA) 
(Sigma-Aldrich Co., St Louis, MO, USA) and 10 mM NaB 
to induce the release of H5-pseudovirions from the surface of 
the producer cells. Supernatants were collected 48 hours post-
transfection, clarified by centrifugation, and stored at -80°C.
Reporter virus pseudotyped with HA from A/Vietnam/ 
1203/2004 (H5-VN-Luc) or A/Whooper Swan/Mongolia/ 
244/05 (H5-WS-Luc) were titered on HEK293T cells. 
Cells were seeded in 96-well plates at 2×104 cells/well in 
Dulbecco’s modified Eagle medium supplemented with 
antibiotics and heat-inactivated fetal bovine serum. The 
following day, cells were inoculated in triplicate with 10-fold 
serial dilutions of pseudovirus stock in the presence of 
8 μg/mL polybrene. At 48 hours post-transduction, cells were 
lysed and assayed for luciferase activity using the ONE-Glo 
Luciferase assay system (Promega Corporation, Fitchburg, 
WI, USA). Luciferase activity was quantified using a Centro 
XS3 LB960 illuminometer (Berthold Technologies, Bad 
Wildbad, Germany) and results reported as relative light 
units (RLU)/mL supernatant.
electrophoresis
For protein analyses in denaturing conditions, 1 μg of 
purified sH5
3
 protein was boiled for 5 minutes in sodium 
dodecyl sulfate (SDS) loading buffer (50 mM Tris, 1% 
β-mercaptoethanol, 2% SDS, 0.005% bromophenol blue, 
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Figure 1 Expression and characterization of H53.
Notes: (A) The HA ectodomain (nucleotides 1–1,723) was amplified from pHW500 and modified by addition of linker sequences, a GCN4pII trimerization domain, and 
His-tag sequences at the 3′ end. (B) SDS-PAGE and Blue Native gel electrophoresis confirmed the expression of the H5 monomer and trimeric forms. (C) A neutralization 
inhibition assay demonstrated that the immunogenicity of trimeric H5 was significantly greater than that of monomeric forms, requiring a lower concentration of protein to 
inhibit 50% of the neutralizing sera (IC50). Error bars represent the standard error of the mean. *Indicates statistical significance. P#0.0243.
Abbreviations: ha, hemagglutinin; h5, h5 hemagglutinin monomer; h53, h5 hemagglutinin trimer; sDs-Page, sodium dodecyl sulfate polyacrylamide gel electrophoresis; 
Ic50, inhibitory concentration 50%.
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and 10% glycerol) and electrophoresed in 10% SDS-PAGE 
(polyacrylamide gel electrophoresis). For analyses in 
non-denaturing gels, 3 μg of purified sH5
3
 protein was mixed 
with Blue Native loading buffer (2 mM EDTA, 20 mM NaCl, 
20 mM Bis-Tris, 10% glycerol, and 0.08% Coomassie Blue 
G-250) and separated on 10% Blue Native PAGE gel con-
taining Bis-Tris, glycerol, and acrylamide in Bis-Tris buffer 
in the outer chamber and Tricine, Bis-Tris with Coomassie 
Blue G250 in the inner chamber. Following electrophoresis, 
gels were stained with Coomassie Blue and imaged with a 
GelDoc XR+ imaging system (Bio-Rad Laboratories Inc., 
Hercules, CA, USA).
Polymer and nanoparticle synthesis
Diacids based on 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
were synthesized as previously described25,26 using 1,6-
dibromohexane, 1-methyl-2-pyrrolidinone, hydroxyben-
zoic acid, N,N-dimethylacetamide, and tri-ethylene glycol 
(Sigma-Aldrich Co.); acetic acid, acetone, acetonitrile, 
dimethyl formamide, potassium carbonate, sulfuric acid, and 
toluene (Thermo Fisher Scientific, Waltham, MA, USA); 
4-p-fluorobenzonitrile (Apollo Scientific, Bredbury, UK). 
Following diacid synthesis, 20:80 CPTEG:CPH copolymer 
was synthesized by melt polycondensation.26 The final compo-
sition of the polymer (23:77 CPTEG:CPH), molecular weight 
(6,055 Da), and purity were determined with 1H nuclear 
magnetic resonance spectroscopy (VXR 300 MHz; Varian, 
Palo Alto, CA, USA). H5
3
-loaded nanoparticles were synthe-
sized using a water-oil-oil double emulsion process.27 First, 
4.5 mg of sH5
3
 was concentrated into 100 μL of nanopure 
water. The solution of sH5
3
 was then added to 45 mg of 20:80 
CPTEG:CPH dissolved in 2.25 mL of methylene chloride and 
homogenized for 90 seconds. The H5
3
-loaded nanoparticles 
were precipitated by pouring the solution into 562.5 mL of 
chilled pentane and collected via vacuum filtration. Blank 
nanoparticles and 1% polyinosinic-polycytidylic acid (poly 
I:C) (InvivoGen, San Diego, CA, USA)-loaded nanoparticles 
were synthesized similarly without water. Scanning electron 
microscopy (Quanta 250; FEI, Hillsboro, OR, USA) was used 
to characterize the size and morphology of the nanoparticles, 
which were found to be consistent with previous work.13 
The encapsulation efficiency of protein was determined by 
degrading 10 mg of nanoparticles in 250 μL of 40 mM sodium 
hydroxide and quantifying the total protein released using a 
microBCA protein kit (Pierce, Rockford, IL, USA).13
Mice
Female BALB/c mice were purchased from Harlan Labo-
ratories (Indianapolis, IN, USA). All mice were housed 
under specific pathogen-free conditions where all bedding, 
caging, water, and feed were sterilized prior to use. Animal 
procedures were conducted with the approval of the Iowa 
State University and University of Nebraska Medical Center 
Institutional Animal Care and Use Committees.
Immunizations
For each formulation, mice were administered a total of 10 μg 
H5
3
. As outlined in Table 1, a portion of the 10 μg H5
3
 dose 
was encapsulated into 50 μg polyanhydride nanoparticles, 
and delivered with or without 250 μg nanoparticles encap-
sulating poly I:C. Blank (ie, no encapsulated protein or poly 
I:C) nanoparticles were used to keep the total amount of 
nanoparticles (300 μg) constant among the different vaccine 
regimens. In addition, control formulations composed of 10 
μg of soluble H5
3
 (sH5
3
) alone, 10 μg of sH5
3
 delivered with 
blank nanoparticles, or 10 μg of sH5
3
 in conjunction with 
10 μg of monophosphoryl lipid A (MPLA) from Salmonella 
enterica (Sigma-Aldrich Co.) were administered. All formu-
lations were suspended in 250 μL (subcutaneous [SC] immu-
nization) or 50 μL (intranasal [IN] immunization) of sterile 
saline. Formulations containing nanoparticles were sonicated 
for 30 seconds to ensure dispersion of particle aggregates 
before immunization. SC immunizations were administered 
Table 1 h53 vaccine formulations
Group Encapsulated H53 Soluble H53 Total 20:80 CPTEG:CPH  
nanoparticles
Additional excipients
h53-nanoparticles 2 μg 8 μg 300 μg –
h53- & poly I:c-nanoparticles 2 μg 8 μg 300 μg 2.5 μg poly I:c
Blank nanoparticles – 10 μg 300 μg –
MPla – 10 μg – 10 μg MPla
sh53 – 10 μg – –
saline – – – –
Abbreviations: cPh, 1,6-bis(p-carboxyphenoxy)hexane; cPTeg, 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane; h53, h5 hemagglutinin trimer; MPla, monophosphoryl 
lipid a; sh53, soluble h5 hemagglutinin trimer.
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at the nape of the neck; IN immunizations were carried out 
using droplet admission via pipettor after administration of 
ketamine/xylazine chemical anesthetic. For “prime/boost/
boost” regimens, booster immunizations were prepared and 
administered the same way as primary immunizations at 
days 21 and 42. Serum samples were obtained at the time 
points indicated via saphenous vein bleeding.
Neutralization assay
Neutralizing antibody assays were carried out using HA-
pseudotyped reporter virus as described previously.22,24 
HEK293T cells were seeded in a 96-well plate at 2×104 cells/
well and grown for 24 hours. Sera samples were serially 
diluted three-fold in culture medium containing 8 μg/mL 
polybrene (Sigma-Aldrich Co.), and mixed with an equal vol-
ume of diluted pseudovirus stock containing 5×104 RLU/mL. 
After incubation at 37°C for 1 hour, virus and serum mixtures 
were added to the cells. Infectivity was evaluated 48 hours 
after transduction using the One-glo Luciferase assay system 
(Promega Corporation). The percentage neutralization was 
calculated as (1- [virus + sera RLU/virus only RLU]) ×100. 
The percentage neutralization for each sera dilution was plot-
ted and neutralizing titers were reported as infectious dose 
50 (ID
50
), calculated as the reciprocal of the serum dilution 
that neutralized 50% of the virus.
A neutralization inhibition assay was used to evaluate 
the immunogenic properties of sH5
3
 protein. Ten-fold serial 
dilutions of sH5 trimer or monomer were incubated at 37°C 
for 30 minutes with a 1:5,000 dilution of pig H5-antiserum 
(Dr Bruce Janke, Iowa State University). Following pre-
incubation with H5 protein, 50,000 RLU of H5-WS-Luc was 
added and the samples incubated for an additional 1 hour at 
37°C and inoculated onto HEK293T cells in 96-well plates. 
At 48 hours after transduction, the levels of luciferase in the 
transfected cells were evaluated using the One-Glo luciferase 
assay system (Promega Corporation) and percentage neutral-
ization was calculated as described above. The percentage 
neutralization at each protein concentration was plotted and 
the half maximal inhibitory concentration (IC
50
) was calcu-
lated as the concentration of soluble H5 protein that inhibited 
50% of the neutralizing activity of the diluted pig sera.
Flow cytometry for T cell memory 
populations
Brachial and axillary lymph nodes were harvested 63 days 
postimmunization and homogenized into single cell suspensions 
in complete tissue culture medium. Single cell populations 
were labeled with 2.5 μM 5-(and-6)- carboxyfluorescein 
diacetate, succinimidyl ester (5[6]-CFDA, SE; CFSE; Thermo 
Fisher Scientific, Waltham, MA, USA). Cells (2.5×105) were 
incubated in 96-well U-bottom plates with 0.5 μg of sH5
3
 
antigen for 96 hours. Cells were aspirated and cell surface 
marker expression and proliferation were evaluated using flow 
cytometry (BD FACSCanto; BD Biosciences, San Jose, CA, 
USA). Cell suspensions were blocked for nonspecific anti-
body binding using 0.1 mg/mL Rat IgG (Sigma-Aldrich Co.) 
and 10 μg/mL mouse anti-CD16/32 (eBioscience, San Diego, 
CA, USA). Fluorescently conjugated antibodies specific for 
murine CD4 and CD8 (eBioscience) were diluted in FACS 
buffer and were used to quantify specific cell populations.
low-pathogenic viral challenge 
and clinical evaluation
The efficacy of H5
3
-based nanoparticle vaccines were evalu-
ated in mice that were challenged at 63 days postimmuniza-
tion with the low pathogenicity influenza virus A/H5N1 
VNH5N1-PR8CDC-RG, obtained from the Centers for 
Disease Control and Prevention (Atlanta, GA, USA). This 
is a PR-8-derived reassortant virus that contains the HA and 
NA genes of H5N1 A/Vietnam/1203/04, a clade 1 virus. Mice 
were anesthetized with 20 mg/mL of xylazine and 100 mg/mL 
of ketamine (1:4 ratio) and inoculated intranasally with 
2.7×103 tissue culture infectious doses 50% (TCID
50
) virus in 
30 μL phosphate-buffered saline. A control group consisting 
of naïve (ie, no vaccine), no challenge (ie, no infection) mice 
were housed similarly throughout the duration of the study. 
Three days after challenge, half of the mice were euthanized 
with 600 μL of 20 mg/mL xylazine and 100 mg/mL ketamine 
delivered via intraperitoneal injection. Bronchoalveolar 
lavage (BAL) fluid was collected as described previously28 
and lung tissue was collected for inflammatory cytokine and 
viral load quantitation (described below). The remaining mice 
were monitored for weight loss for 2 weeks postchallenge 
before being removed from study.
Virus load quantitation
Following the procedure of Alsharifi et al lung tissue was pre-
served in 3 mL of RNAlater Stabilizing Reagent (Qiagen NV, 
Venlo, the Netherlands).29 Tissue was held submerged in 
the RNAlater for 3 days at 4°C. Tissues were then removed 
from the RNAlater, weighed, and cut into 30 mg pieces and 
individually frozen at -80°C in 1.5 mL microcentrifuge 
tubes. For the extraction process (total RNA), individual 
30 mg tissue pieces were homogenized in 200 μL buffer 
RLT (RNeasy Mini Kit, Qiagen NV) using a disposable 
pellet pestle (Thermo Fisher Scientific) in conjunction with 
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a cordless motor (Thermo Fisher Scientific). An additional 
400 μL of buffer RLT was added to each tube after homog-
enization was completed. Tissue was extracted into 60 μL 
final volume in sterile, RNase-free H
2
O (Qiagen NV) and 
frozen at -80°C until polymerase chain reaction (PCR) was 
performed. Samples containing the extracted RNA were 
thawed, mixed well, and the total RNA concentration was 
determined, in duplicate measurements, using the Nanodrop 
method for RNA content. Total RNA concentration for each 
sample was adjusted to 40 μg/μL, and 5 μL was used as the 
template for the PCR reaction. PCR was performed on an 
Applied Biosystems 7500 Fast Real-Time PCR System, on 
the standard mode, using AgPath-ID One-Step RT-PCR 
Reagents (Thermo Fisher Scientific, Waltham, MA, USA) 
in conjunction with the Fast-Track Diagnostics FTD-21-
96/12 Kit (Junglinster, Luxembourg), which contains bome 
mosaic virus (BMV) internal PCR extraction control, positive 
control, and primer/probes for universal influenza A antigen. 
For the standard curve, normal, non-influenza–challenged 
mice lungs (naïve controls) were homogenized using the 
procedure outlined above. RNA from stock influenza A H5 
virus was extracted using the Qiagen QiAmp Viral RNA Kit 
Mini Kit (Qiagen NV). Extracted RNA was quantified using 
the Nanodrop procedure. For the standard curve, ten-fold 
dilutions of the H5-extracted viral RNA were mixed with 
extracted RNA from the normal mouse lungs that had been 
standardized to 40 ng/μL. Standard curves were obtained 
with each set of PCR reactions.
Cytokine analysis of BAL fluid
BAL fluid samples collected 3 days post-viral challenge 
were analyzed for the inflammatory cytokines IL-6, IP-10, 
MIG, G-CSF, IFN-g, MCP-1, KC, and MIP-2 using a 
MILLIPLEX® MAP assay kit (EMD Millipore, Billerica, 
MA, USA). The assay was performed according to manufac-
turer instructions. Briefly, 25 μL of BAL fluid, 25 μL assay 
buffer, and 25 μL MILLIPLEX MAP beads were added 
to each well of a 96-well plate. After shaking overnight at 
4°C, the plate was washed and incubated with 25 μL/well 
detection antibody for 1 hour at room temperature. Follow-
ing, 25 μL/well of streptavidin phycoerythrin was added 
for an additional 30 minutes. The plate was washed once 
more before measuring fluorescence intensity on a Bio-Plex 
200 system (Bio-Rad Laboratories Inc.).
Principal component analysis
Previously, principal component analysis (PCA) was used to 
identify pathogen-mimicking capabilities of polyanhydride 
nanoparticles in comparison to bacteria.30 In this study, PCA 
was used to mathematically capture the similarities among 
the different vaccine formulations tested and their immune 
responses. A linear data dimensionality reduction method31–33 
was used to condense eight-dimensional data (neutralizing 
antibody titer, viral load, and six cytokine concentrations) 
into two dimensions (ie, principal components [PC]). In 
this work, PC1 was a linear combination of viral load and 
cytokine concentration(s), while PC2 primarily captured 
neutralizing antibody titer. At least 90% of the variance was 
captured between these two PCs. Similarities among data 
were mathematically represented as the proximity between 
data points (ie, data points close together are more similar 
than data points farther apart).
statistics
Statistical significance among formulations (P#0.05) was 
determined by one-way analysis of variance (ANOVA) 
followed by Tukey’s post-test using Graph Pad Prism (v6.01; 
Graph Pad Software, Inc., La Jolla, CA, USA).
Results
Characterization of soluble H5 trimer 
protein (sh53)
A recombinant baculovirus containing the ectodomain of 
HA from A/Whooper Swan/Mongolia/244/05 (Figure 1A) 
was expressed in Sf9 insect cells and the secreted soluble H5 
trimer (sH5
3
) protein was purified from culture supernatant 
by affinity chromatography using nickel agarose beads. 
Analyses of the purified protein by electrophoresis in SDS-
PAGE and Blue Native gels indicated the predominant form 
of sH5
3
 protein was trimeric (Figure 1B). A neutralization 
inhibition assay was used to determine whether the sH5
3
 
retained neutralizing epitopes of native virus (Figure 1C). 
In this assay, convalescent pig sera containing high titers of 
H5-neutralizing antibody was incubated with serial dilutions 
of sH5
3
 or sH5 monomer and tested for neutralizing activity 
against H5-WS-Luc pseudotyped reporter virus. The HA 
presented in its native trimeric state has been found to be more 
immunogenic than the monomeric form.5,8 Similarly, we 
observed that while both the monomeric and trimeric forms 
of sH5 inhibited neutralizing antibody at fmol concentrations, 
the inhibitory activity of the sH5
3
 trimer was about 2.5-fold 
higher than that of the monomer.
Immunogenicity of soluble recombinant 
h5 ha trimer
BALB/c mice (6–8 weeks) were immunized either subcu-
taneously or intranasally with 10 μg of soluble protein at 0, 
21, and 42 days and sera collected at 21, 42, and 63 days 
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postimmunization were tested for neutralizing antibody 
against the homologous H5-WS-Luc pseudovirus. No neu-
tralizing antibody was detected at day 21 following primary 
immunization (Figure 2A). By day 42, the majority of mice 
in both immunization groups had detectable neutralizing 
antibody titers (ie, .50) that were greater than protective 
titers reported in the literature.7,8 However, the response was 
highly variable among individual mice, with ID
50
 titers rang-
ing from undetectable to greater than 1,000. Neutralization 
titers significantly increased following a second boost 
(day 63), with mean neutralization antibody titers of greater 
than 10,000. In addition, there was less variability in the 
neutralizing antibody titers among individual mice, especially 
those immunized subcutaneously.
As highly pathogenic H5N1 has continued to spread in 
avian and mammalian hosts, different lineages have emerged 
that are now classified into distinct, but phylogenetically 
related clades.1 To examine the cross-clade breadth of the 
neutralizing antibody response elicited with A/Whooper 
Swan/Mongolia/244/05-based sH5
3
 (clade 2.2), day 63 sera 
was tested for neutralizing activity against H5-VN-Luc, 
a luciferase reporter virus pseudotyped with HA from the 
A/Vietnam/1203/2004 HA, an H5 clade 1 strain. Although 
the cross-clade neutralization titers were 2–10-fold lower 
than titers to homologous virus, serum samples from all mice 
were able to neutralize Vietnam/1203 pseudotyped virus, 
with mean neutralizing antibody titers of 1,000 (Figure 2B). 
Together, these data indicate that nonadjuvanted sH5
3
 antigen 
is able to elicit high titers of H5 cross-clade neutralizing anti-
body when administered using a prime/boost/boost regimen. 
Consistent with previous reports,6,7,12 multiple immunizations 
of sH5
3
 recombinant protein were required to generate con-
sistently high neutralizing antibody titers.
Neutralizing antibody response in mice 
vaccinated with h53-based nanovaccines
Our previous studies showed that polyanhydride nano-
vaccines enhanced the immune response to recombinant 
proteins.13–15 Therefore, we examined the immune response of 
sH5
3
 delivered with and/or encapsulated into polyanhydride 
nanoparticles (Table 1). Mice were immunized subcutane-
ously with either a single-dose regimen or a prime/boost/
boost regimen of three immunizations 21 days apart. Serum 
was collected at 42 and 63 days postimmunization and tested 
for neutralizing antibody titers against H5-WS-Luc. As we 
observed above, sH5
3
 alone elicited low neutralizing titers in 
the absence of booster immunizations, with most mice having 
ID
50
 titers of less than 100 through 63 days postimmunization 
(Figure 3). Higher titers were observed using a single-dose 
immunization regimen with sH5
3
 in the presence of adjuvant, 
with MPLA eliciting higher neutralizing antibody titers than 
any of the nanovaccine formulations or sH5
3
 alone. In the 
absence of booster immunizations, the neutralizing antibody 
titers in sera from mice immunized with nanovaccine formu-
lations was lower than that from the MPLA-treated mice at 
42 days, with the exception of the formulation including poly 
I:C; however, there were a greater number of single-dose, 
nanoparticle-vaccinated mice with detectable neutralizing 
antibodies than in mice vaccinated once with sH5
3
 alone. 
Administration of one or two booster vaccinations resulted in 
enhanced neutralizing antibody titers in all the formulations. 
The highest and most consistent titers were observed after 
A
105 Subcutaneous
Subcutaneous
Intranasal
Intranasal
104
103
102
105
104
103
102
21
Days postimmunization
42 63 WS VN03 WS VN03
ID
50
B
ID
50
Figure 2 Immunogenicity of soluble h53 antigen.
Notes: (A) Mice were immunized subcutaneously or intranasally with 10 μg soluble h53 on days 0, 21, and 42. Sera collected at days 21, 42, and 63 after primary immunization 
were tested for neutralizing antibody. Neutralizing antibody titers were not detected until after the second immunization; however, titer generated by days 42 and 63 were robust. 
(B) The neutralizing antibody titers demonstrated cross-clade protection at 63 days with both immunization routes. Error bars represent the standard error of the mean.
Abbreviations: h53, h5 hemagglutinin trimer; ID50, sera dilution that inhibits 50% of pseudovirus infectivity.
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receiving three immunizations (prime/boost/boost regimen, 
day 63), with little difference observed among the different 
formulations (Figure 3).
cell-mediated immune response
Cell-mediated immune responses are often associated with 
broader protective immunity and can play an important role in 
protection against antigenically diverse strains of influenza.18,19 
Therefore, we examined the proliferative T cell populations 
on day 63 (ie, 21 days after the last immunization) in mice 
receiving the prime/boost/boost regimen (Figure 4). Draining 
lymph nodes were removed and homogenized to single cell 
suspensions and labeled with CFSE to observe proliferating 
cell populations. After 96 hours of ex vivo stimulation with 
sH5
3
, CD4+ T cells were quantified via flow cytometry. 
A significant expansion of CD4+ T cells was observed in all 
groups of vaccinated mice as compared to mice receiving 
saline alone. In addition, the inclusion of poly I:C within 
the nanovaccine formulation resulted in significantly higher 
numbers of CD4+ T cells as compared to mice immunized 
with sH5
3
 alone or sH5
3
 adjuvanted with MPLA. These data 
suggest that inclusion of nanoparticles encapsulating poly 
I:C to induce an appropriate innate immune response may 
enhance antigen-specific adaptive immune responses.
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Figure 3 The neutralizing antibody responses to H53-polyanhydride nanovaccines were examined 42 and 63 days post-primary immunization.
Notes: Single-dose vaccination regimens utilizing poly I:C encapsulated with H53 demonstrated neutralization titers similar to a MPLA-adjuvanted control at day 42, with 
most of the remaining formulations reaching equivalency at day 63. The use of a prime/boost/boost immunization regimen enhanced the production of neutralizing antibodies 
and reduced mouse-to-mouse variability. Error bars represent the standard error of the mean. Different letters indicate statistical significance among treatments of the 
same regimen (ie, single dose or prime/boost/boost) at each time point. *Indicates statistical significance between the different regimens for each treatment. No statistical 
significance was observed when comparing between the various prime/boost/boost formulations. P#0.0434.
Abbreviations: h53, h5 hemagglutinin trimer; MPla, monophosphoryl lipid a; sh53, soluble h5 hemagglutinin trimer; ID50, sera dilution that inhibits 50% of pseudovirus 
infectivity; poly I:c, polyinosinic-polycytidylic acid.
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Figure 4 enhanced cD4+ T cell memory with poly I:c polyanhydride nanovaccine.
Notes: Draining lymph nodes were harvested from prime/boost/boost immunized 
mice 63 days after the primary immunization. Ex vivo antigen stimulation and CFSE-
labeling demonstrated enhanced cD4+ T cell proliferation of mice immunized 
with poly I:c nanovaccines. error bars represent the standard error of the mean. 
Different letters indicate statistical significance among treatments. P#0.0147.
Abbreviations: CFSE, 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester; 
MPla, monophosphoryl lipid a; sh53, soluble h5 hemagglutinin trimer; poly I:c, 
polyinosinic-polycytidylic acid..
h53 vaccination protects against live-viral 
challenge
To examine the efficacy of H5
3
-loaded nanoparticles in 
protection from clinical disease, mice were vaccinated 
with various nanovaccine formulations (Table 1) using a 
prime/boost/boost regimen and challenged at day 63 with 
the low-pathogenic VNH5N1-PR8/CDC-RG, a reverse 
genetics-derived influenza virus containing the HA and 
NA genes of A/Vietnam/1203/04 (H5N1) virus in the 
genetic background of the high-growth master strain 
A/Puerto Rico/8/34 (H1N1). Pre-challenge antibody response 
to the various vaccine regimens was evaluated in serum 
collected 1 week before challenge. All vaccinated groups 
had high levels of total anti-H5
3
 IgG, with no significant dif-
ference among the groups. Similar to our earlier studies, all 
vaccinated mice had detectable neutralizing antibody titers 
of greater than 100 to the clade 2.2 H5-WS-Luc pseudotyped 
reporter virus, with mean titers among the group ranging 
between 3,000–4,000 (Figure S1).
The body weight of each mouse was observed for 14 days 
postchallenge. All of the vaccine formulations protected 
mice from challenge with body weight increasing postchal-
lenge similar to naïve mice that were not challenged (Fig-
ure 5A). In contrast, mice receiving saline immunizations 
began to lose a significant proportion of their body weight 
approximately 5 days postchallenge. Saline-administered 
mice continued to lose approximately 20% of their total 
weight by 8 days postchallenge before recovering. Based 
on clinical response, as measured by weight loss, all vaccine 
regimens induced a protective immune response and there 
was no significant difference among the various vaccine 
regimens.
At 3 days postchallenge, half of the mice in each group 
were sacrificed and lung homogenates were assayed for virus 
load using quantitative reverse transcription PCR as described 
previously.34 All vaccinated mice showed significant reduc-
tion in virus load upon challenge as compared to the virus 
load in the saline-administered mice (Figure 5B). A wide 
mouse-to-mouse variability in virus load was observed for all 
vaccine regimens, with no significant differences among the 
groups in mean virus loads. However, a correlation between 
pre-challenge (day 56 post-primary immunization) neutral-
izing antibody titer and virus load (day 3 postchallenge) was 
observed (Figure 5C).
Finally, a multiplexed assay was used to quantitate the 
concentrations of inflammatory cytokines (IL-6, IP-10, 
G-CSF, IFN-γ, MCP-1, KC, and MIP-2) present in BAL 
fluid. Vaccinated mice had low levels of inflammatory cytok-
ines 3 days postchallenge similar to the naïve, no challenge 
controls (Figure S2). In contrast, mice receiving saline had 
significantly greater concentrations of most inflammatory 
cytokines postchallenge with the exception of IFN-γ (data 
not shown).
clinical signs postchallenge in mice 
vaccinated with h53-nanoparticles are 
similar to healthy naïve, noninfected mice
PCA was utilized to capture the complex relationships 
between the neutralizing antibody titer, viral load, and six 
inflammatory cytokine measurements discussed above. 
Following infection, saline-administered mice (ie, immu-
nologically naïve) had the most unique behavior because 
this was the only treatment group with any significant PC1 
values (Figure 6A). The PC1 dimension captured the largest 
amount of independent data and was a linear combination of 
viral load and cytokine concentration. In contrast, the PC2 
dimension was primarily captured by neutralizing antibody 
titer. While all of the H5
3
 vaccine formulations demon-
strated similar PC1 values, mice receiving the ‘H5
3
- & poly 
I:C-nanoparticle’ formulation or ‘sH5
3
’ showed the most 
significant PC2 values, or variability in neutralizing antibody 
among animals. Therefore, saline-administered mice have 
the behavior most unlike the remaining formulations, and 
neutralizing antibody titer is the most unique of the descrip-
tors used in the analysis.
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Figure 5 Mice were protected upon challenge with low pathogenic VNH5N1-PR8/CDC-RG.
Notes: (A) Mice were challenged with a reverse genetics-derived influenza virus, VNH5N1-PR8/CDC-RG, containing the HA and NA genes of A/Vietnam/1203/04 (H5N1) 
virus in the genetic background of the high-growth master strain A/Puerto Rico/8/34 (H1N1). Body weight was observed for 2 weeks postinfection. All vaccinated mice 
maintained or gained weight similar to healthy naïve, no challenge mice. (B) Viral load in lung homogenates collected at 3 days post-challenge, (C) which correlated with the 
pre-challenge neutralizing antibody titers. Different letters indicate statistical significant among treatments.
Abbreviations: h53, h5 hemagglutinin trimer; ha, hemagglutinin; ID50, sera dilution that inhibits 50% of pseudovirus infectivity; Na, neuraminidase; sh53, soluble h5 
hemagglutinin trimer; TcID50, tissue culture infectious dose 50%.
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Figure 6 h53-nanoparticle responses most similar to healthy naïve, no challenge mice. 
Notes: (A) Principal component analysis was performed utilizing neutralizing antibody titer, viral load, and inflammatory cytokine measurements, with each data point 
representing one mouse. all vaccination formulations were found to be very different from saline-administered mice, as evidenced by the small and high Pc1 values, 
respectively. (B) PCA displaying average values after the exclusion of saline-administered mice and neutralizing antibody titers. The H53-nanoparticle formulation induced 
responses very similar to healthy, noninfected mice. 
Abbreviations: h53, h5 hemagglutinin trimer; Pc, principal components; Pca, principal component analysis.
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In addition to the primary correlations uncovered by 
correlations to saline-administered mice and neutralizing 
antibody titers, more subtle relationships in the data remained 
hidden. Thus, the analysis was repeated after excluding the 
primary correlations (ie, saline-administered mice and neu-
tralizing antibody titer) and is shown in Figure 6B, where 
only the average value of each treatment is displayed for clar-
ity. The ‘H5
3
-nanoparticle’ formulation induced a response 
postchallenge similar to the healthy naïve, nonchallenged 
(ie, control) mice, as seen by the close proximity of the 
average data points (Figure 6B). Mice receiving soluble H5
3
 
alone (sH5
3
) also resulted in responses similar to the control 
mice, but less so than the ‘H5
3
-nanoparticle’ formulation. 
This analysis demonstrated that all the vaccine formulations 
resulted in a significant improvement in clinical responses 
when compared to the saline-treated, infected mice, while 
the ‘H5
3
-nanoparticle’ formulation induced responses most 
similar to healthy control mice.
Discussion
The design of effective vaccines for the prevention of 
influenza is a challenging task. Despite best efforts, the 
2013–2014 US seasonal influenza vaccine was shown to be 
~60% effective in patients.35 In the case of pandemic influ-
enza, such as H5N1, the efficacy of vaccines can be even 
further reduced. Currently, the approved H5N1 influenza 
vaccine consists of two large doses (90 μg) administered 
28 days apart, but is only 45% effective.36 In this work, we 
examined an alternative to conventional influenza vaccines 
through the use of polyanhydride nanoparticles. By encap-
sulating H5 antigen into polyanhydride nanoparticles, the 
foundation has been laid for the design of pandemic influenza 
vaccines with improved efficacy by demonstrating reduced 
variability in the neutralizing antibody titer, enhanced T cell 
responses, and greater stability.20
As mentioned above, the recent seasonal influenza vac-
cine is approximately 60% effective; however, this estimate 
has a 95% confidence interval of 5%–68%,35 which is a 
substantial range that indicates the large (and unacceptable) 
variability of the host responses to the vaccine. Variability of 
vaccine effectiveness can be influenced by a large number of 
factors, including age, obesity, nutrition, or other disease(s) 
present in the host.37–39 While the vaccine formulations used 
in this work performed similarly, one of the strengths of 
the polyanhydride nanovaccine is illustrated in its ability to 
reduced immune response variability. Immunizations with 
H5
3
-nanoparticles were shown to induce more consistent 
neutralizing antibody titers with less variability compared 
to other formulations (Figures 3 and S1). In addition, PCA, 
which incorporated the neutralizing antibody titer, viral 
load, and inflammatory cytokine data postchallenge, indi-
cated that H5
3
-nanoparticle vaccination led to consistent 
immune responses (Figure 6A). Similarly, H5
3
-nanoparticle 
immunized mice did not exhibit clinical signs of disease 
postchallenge and were the most similar to healthy (naïve, 
noninfected) mice (Figure 6B).
Aside from variability in immune responses, many 
vaccines struggle to stimulate T cell immunity. Although 
humoral immunity is often sufficient to provide protection 
against homologous strains of influenza, cell-mediated 
immunity is necessary when confronting heterologous 
variants.18 CD8+ T cells secrete antiviral cytokines and often 
have a broader epitope spectrum than that of the humoral 
response.18,19 While not fully understood, CD4+ T cells play 
a role in protection against heterologous influenza infection 
by producing cytokines to restrict viral replication and even 
providing some lytic activity as well.18,19,40 Vaccines that can 
stimulate both humoral and cell-mediated immunity would 
likely have an advantage in cross-clade protection. The 
H5
3
 antigen used in this work demonstrated the induction 
of cross-reactive neutralizing antibodies when delivered 
alone (Figure 2). However, when delivered in the context of 
polyanhydride nanoparticles, CD4+ T cell proliferation was 
enhanced upon ex vivo stimulation with antigen (Figure 4). 
The nanovaccine formulation containing poly I:C induced the 
greatest proliferation of CD4+ T cells. It is known that poly 
I:C signaling through TLR3 induces the production of several 
Th1 and Th2 cytokines, as well as type I interferons,41 which 
may explain the T cell expansion observed in Figure 4.
Finally, we believe that the ability to encapsulate influ-
enza antigens into polyanhydride nanoparticles will provide 
additional benefits, including dose sparing and enhanced 
shelf-life characteristics.15,42 While many of the nanoparticle 
formulations used in this study performed similarly to soluble 
antigen delivered alone, it is likely that the 10 μg dose of 
the highly immunogenic H5
3
 antigen masked the advantages 
provided by the polyanhydride nanoparticles. Previously, it 
has been demonstrated that encapsulation of a suboptimal 
dose of antigen into polyanhydride particles induced similar 
antibody titers to administration of 64-fold higher soluble 
antigen alone.15 The ability to reduce antigen per dose (and 
therefore increase vaccine availability) and optimize single-
dose formulations will be paramount in providing rapid 
protection upon a pandemic outbreak of H5N1. Finally, 
polyanhydride nanovaccines exhibit release of immunogenic 
protein even when stored at room temperature for 1 year.42 
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This ability for a vaccine to be stored at room temperature 
would be a major benefit in terms of maintaining stockpiles 
of pandemic vaccines.
Conclusion
The studies presented herein demonstrate the strong immu-
nogenic properties of the recombinant H5
3
 antigen developed 
for these studies as well as the immune responses to H5
3
-
loaded polyanhydride nanovaccines. All formulations were 
able to induce detectable mean neutralizing antibody titers 
42 days postvaccination. The formulation including poly 
I:C also conferred the additional advantages of enhanced 
antibody titers at earlier time points and induction of pro-
liferative T cell responses. All vaccine formulations were 
able to induce protection against a low-pathogenic, live-viral 
challenge. Of interest, PCA demonstrated that after viral 
challenge, the mice immunized with the H5
3
-nanoparticle 
formulation were as healthy as naïve, nonchallenged mice 
and this formulation induced less variable immune responses. 
The current studies provide a foundation to further exploit 
the advantages of polyanhydride nanoparticle-based subunit 
vaccines against influenza.
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Figure S1 Prime/boost/boost immunized mice induced protective neutralizing antibody titers.
Notes: Mice immunized with the various formulations were challenged with a low pathogenic influenza virus 63 days after the initial vaccination. One week before the 
challenge, all vaccine formulations induced high neutralizing antibody titers consistent with previous work and were suggested to be protective. Error bars represent the 
standard error of the mean. Different letters indicate statistical significance among treatments. P#0.0001.
Abbreviations: ID50, sera dilution that inhibits 50% of pseudovirus infectivity; h53, h5 hemagglutinin trimer; sh53, soluble h5 hemagglutinin trimer.
Figure S2 Low levels of inflammatory cytokines were present in immunized mice postchallenge.
Notes: Saline-administered mouse lungs had significant increases in inflammatory cytokines 3 days postchallenge. In contrast, the lungs of H53-immunized mice had low levels 
of inflammatory cytokines similar to healthy, noninfected mice.
Abbreviations: h53, h5 hemagglutinin trimer; sh53, soluble h5 hemagglutinin trimer.
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